Drug
Aln Hsd
Aln Hsd: highest development phase Phase 2, developed by Alnylam Pharmaceuticals, Regeneron. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals, Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-HSD NCT05519475 | Phase 2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) |
| ALN-HSD NCT04565717 | Phase 1 | Nonalcoholic Steatohepatitis |
Latest
No recent events.
Follow Aln Hsd on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.